🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

26 recruiting trials

for Graft-versus-leukemia

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant NCT06996119Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor NCT07238712Phase 21 site📍 Saint Petersburg St. Petersburg State Pavlov Medical University · Tests: Ruxolitinib, Abatacept (Orencia) The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation NCT05436418Phase 1, Phase 22 sites📍 Duarte📍 Bethesda National Cancer Institute (NCI) · Tests: Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523n/a1 site📍 Xining Yigeng Cao,MD,PhD Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) NCT03970096Phase 23 sites📍 Tampa📍 Pittsburgh📍 Seattle Fred Hutchinson Cancer Center · Tests: Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives NCT00001529n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: G-CSF Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, None-placebo, Busulfan (BU) Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants NCT00106925n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies NCT07366801Phase 2, Phase 31 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®), Abatacept Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome NCT06128070Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide NCT03533816Phase 12 sites📍 Westwood📍 Columbus University of Kansas Medical Center · Tests: EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning NCT06815003Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cy… A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites📍 Birmingham📍 Duarte📍 Palo Alto Center for International Blood and Marrow Transplant Resear… · Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies NCT07565220Phase 11 site📍 Pittsburgh Sawa Ito, MD · Tests: Thiotepa, Fludarabine, Busulfan, PBSC infusion Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684Phase 220 sites📍 Amiens📍 Angers📍 Besançon University Hospital, Clermont-Ferrand · Tests: Fecal Microbiota Transplantation Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis NCT06756152Phase 2, Phase 31 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarab… Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy NCT03555851n/a1 site📍 Charlotte Wake Forest University Health Sciences · Tests: Cyclophosphamide, Specimen collection PTCy and ATG for MSD and MUD Transplants NCT06299462Phase 1, Phase 21 site📍 Rio de Janeiro Instituto Nacional de Cancer, Brazil · Tests: ATG 5.0, Cyclophosphamide injection, ATG 4.0 Cord Blood Transplantation in Children and Young Adults With Blood Cancer NCT07566377Phase 21 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR NCT02416388Phase 2, Phase 356 sites📍 Amiens📍 Angers📍 Argenteuil University Hospital, Angers · Tests: Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways NCT05124288n/a1 site📍 Milan Ciceri Fabio · Tests: Observations on Relapsed AML Allogeneic Transplanted patients Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL NCT07297914Phase 2, Phase 39 sites📍 Vienna📍 Prague📍 Copenhagen Bambino Gesù Hospital and Research Institute · Tests: Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab, Cyclophosphamide, Total Body Irradiation 12 Gy Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245Phase 22 sites📍 Columbus📍 Houston Ohio State University Comprehensive Cancer Center · Tests: Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collec… Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation NCT07249346Phase 23 sites📍 Birmingham📍 Boston📍 Columbus Hannah Choe, MD · Tests: Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning NCT03852407Phase 210 sites📍 Antwerp📍 Bruges📍 Brussels University of Liege · Tests: Thymoglobulin, Melphalan, Fludarabine, Cyclophosphamid Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) NCT06462365Phase 15 sites📍 Duarte📍 Boston📍 Minneapolis Tr1X, Inc. · Tests: TRX103
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy